Resources

April 24, 2023 | Posters & Presentations
Oral Formulation Development of the Anti-Angiogenesis Drug D-4517.2 to Treat Age-related Macular Degeneration (wet AMD) and Diabetic Macular Edema (DME)
April 18, 2023 | Posters & Presentations
A Potent Macrophage Switching Drug D-4559 Reduces Tumor Growth in a Hepatocellular Carcinoma Mouse Model
April 1, 2023 | Publications
Targeted Nanomedicine: Ashvattha Therapeutics’ Path to Developing Hydroxyl Dendrimers
March 20, 2023 | Media
Scrip Asks…What Does 2023 Hold For Biopharma? Part 8: Therapeutic Area Advances
February 20, 2023 | Media
First patient enrolled in phase 1/2 study of hydroxyl dendrimer imaging agent
January 6, 2023 | Media
Economic Forecast 2023: New challenges in biotech’s ‘valley of death’
October 20, 2022 | Media
Biospace Movers & Shakers: Maravai, Predictive Oncology, Exagen and More Tap New Execs
September 29, 2022 | Posters & Presentations
WMIC 2022

Preclinical data demonstrating hydroxyl dendrimer (HD)-based PET tracer, [18F]OP-801 can be reproducibly synthesized and is suitable for human use.

September 29, 2022 | Posters & Presentations
WMIC 2022

Preclinical data demonstrating that our hydroxyl dendrimer (HD)-based PET tracer, [18F]OP-801, can detect activated macrophages and microglia with high sensitivity and specificity in an experimental autoimmune encephalomyelitis (EAE) murine model of multiple sclerosis (MS).

September 12, 2022 | Media
Enrollment underway in phase 2 study of subcutaneous anti-VEGF wet AMD, DME candidate